Suppr超能文献

肌酐的酶法检测:行动时刻。

Enzymatic assays for creatinine: time for action.

作者信息

Panteghini Mauro

机构信息

Centre for Metrological Traceability in Laboratory Medicine (CIRME) and Department of Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.

出版信息

Scand J Clin Lab Invest Suppl. 2008;241:84-8. doi: 10.1080/00365510802149978.

Abstract

Estimation of glomerular filtration rate (eGFR) on the basis of serum creatinine concentration measurements using equations is critical to ongoing global public health efforts to improve the diagnosis and treatment of chronic kidney disease. There is now ongoing activity to promote world-wide standardization of methods to measure creatinine concentrations, together with the introduction of a revised eGFR equation appropriate for use with standardized creatinine methods. Standardization of calibration, i.e. implementation of calibration traceable to higher-order reference measurement procedures and reference materials, does not, however, correct for analytical interferences of field methods (non-specificity bias). To account for the sensitivity of alkaline picrate-based methods to non-creatinine chromogens, some manufacturers have adjusted the calibration to minimize the pseudo-creatinine contribution of plasma proteins, thereby producing results more closely aligned with the reference method (isotope dilution-mass spectrometry), but this strategy makes the assumption that the non-creatinine chromogen interference is constant among samples, which is an oversimplification. Thus, analytical non-specificity for substances found in individual patient samples affects the accuracy of eGFR computed from serum creatinine concentrations for any alkaline picrate method, including the so-called "compensated" Jaffe methods. Using assays that are more specific for serum creatinine, such as those based on enzymatic reactions, may provide more reliable eGFR values. Supporting the choice of more specific assays by clinical laboratories is one of the main tasks of our profession in achieving the ultimate clinical goal, which is to routinely report an accurate eGFR in all pertinent clinical situations.

摘要

基于血清肌酐浓度测量值使用公式估算肾小球滤过率(eGFR)对于全球改善慢性肾脏病诊断和治疗的公共卫生努力至关重要。目前正在开展活动,以促进肌酐浓度测量方法的全球标准化,并引入适用于标准化肌酐方法的修订版eGFR公式。然而,校准的标准化,即实施可溯源至更高阶参考测量程序和参考物质的校准,并不能校正现场方法的分析干扰(非特异性偏差)。为了考虑基于碱性苦味酸盐的方法对非肌酐色原的敏感性,一些制造商调整了校准,以尽量减少血浆蛋白的假肌酐贡献,从而使结果更接近参考方法(同位素稀释-质谱法),但这种策略假设非肌酐色原干扰在样本之间是恒定的,这是一种过度简化。因此,个体患者样本中物质的分析非特异性会影响任何碱性苦味酸盐方法(包括所谓的“补偿”Jaffe方法)根据血清肌酐浓度计算的eGFR的准确性。使用对血清肌酐更具特异性的检测方法,如基于酶促反应的检测方法,可能会提供更可靠的eGFR值。支持临床实验室选择更具特异性的检测方法是我们专业实现最终临床目标的主要任务之一,该目标是在所有相关临床情况下常规报告准确的eGFR。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验